Cerenome, Inc. (CNSY)

Market Cap	21.27M -66.0%
Revenue (ttm)	4.20M -21.0%
Net Income	-26.09M
EPS	-4.37
Shares Out	6.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,269
Open	3.100
Previous Close	3.200
Day's Range	3.085 - 3.130
52-Week Range	2.900 - 23.425
Beta	1.42
Analysts	Strong Buy
Price Target	36.00 (+1,065.05%)
Earnings Date	Aug 14, 2026

About CNSY

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary li...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: CNSY
• Website: https://cerenome.com

Financial Performance

In 2025, Cerenome's revenue was $5.21 million, a decrease of -10.49% compared to the previous year's $5.82 million. Losses were -$22.39 million, 72.5% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for CNSY stock is "Strong Buy." The 12-month stock price target is $36.0, which is an increase of 1,065.05% from the latest price.

Price Target

$36.0

(1,065.05% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 18, 2026

Data Sources Report a data error